Healthcare Industry News: Chugai
News Release - December 2, 2008
Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
BASKING RIDGE, N.J., Dec. 2 -- (Healthcare Sales & Marketing Network) -- Regado Biosciences, Inc., announced today the appointment of Ellen McDonald to the newly created position of Senior Vice President of Business Operations and Chief Business Officer, effective immediately. Ms. McDonald brings to Regado nearly 20 years of experience in the biopharmaceutical industry, with expertise heading business development, operations, portfolio management and marketing. She will report to David J. Mazzo, Ph.D., the Company's President and Chief Executive Officer.Dr. Mazzo stated, "Ellen has made critical contributions to Regado as a senior consultant, and we are very pleased to announce she is joining the Company's management team. She has a substantial track record in building commercial enterprises and in spearheading the growth of pharmaceutical product portfolios. These capabilities will be invaluable as we further accelerate our lead therapeutic programs." Regado recently completed enrollment in a Phase IIa clinical study (REVERSAL-PCI) of its most advanced therapeutic candidate, the REG1 Anticoagulation System, in patients undergoing elective percutaneous coronary intervention.
Most recently, Ms. McDonald served as Senior Vice President and Chief Business Officer at Aeterna Zentaris, and, prior to that, Senior Vice President, Business Operations at Chugai Pharma USA. At both firms, she had a key role in establishing new directions for the enterprise and facilitating relationships with the financial community. Previously, Ms. McDonald served as Senior Vice President, Cardiovascular Marketing and Medical at Bristol-Myers Squibb, managing a $4.25 billion portfolio of cardiovascular products and a budget of $400 million. She was responsible for leading the growth in sales of Plavix®, the second-largest-selling drug in the world last year, Pravachol® and Avapro®. Ms. McDonald began her career in the pharmaceutical industry at Johnson & Johnson, where she rose to the leadership of the company's largest pharmaceutical franchise as Vice President, Oncology at Ortho Biotech.
Ms. McDonald is a Director of Cobalis Corporation and a member of the Women's Foreign Policy Group. She earned a Bachelor of Science in General Engineering at the United States Military Academy, West Point, following which she served for five years abroad with the U.S. Army. She also earned a Masters of Business Administration in the Executive Program at Columbia University.
About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.
Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.
Source: Regado Biosciences
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
